arrow

news

PANBioRA Kick-off meeting: solution for a cost-and time-effective risk assessment of biomaterials

February 12th, 2018

PANBioRA Kick-off meeting: solution for a cost-and time-effective risk assessment of biomaterials

PANBioRA Kick-off meeting: solution for a cost-and time-effective risk assessment of biomaterials

The EU-funded project PANBioRA -PersonalisedAnd/orGeneralised Integrated Biomaterial Risk Assessment has kicked off in January 2018. For the next four years, 17 project partners will collaborate to develop a standardized solution for the evaluation of biomaterials.

Biomaterial-based solutions compromise a significant portion of remedies offered by the healthcare system. However, the currently available methodologies are not sufficient for proper risk assessment of all biomaterial applications. PANBioRA aims at providing a set of tools (protocols and instruments) that can standardize the evaluation of new biomaterials. Moreover, this method will allow for pre-implantation, personalized diagnosis for biomaterial-based applications that will ensure better clinical outcomes and minimize the risks related to the use of established and new biomaterials.

From 30 - 31 January the PANBioRApartners celebrated their kick-off meeting in Brussels. The Project Officer from the European Commission attended on the first meeting day. After a presentation of the project’s main objectives and tasks by the scientific coordinator Protip Medical, the administrative coordinator Steinbeis 2i GmbH presented guidelines for the overall EU-project management. Following this, each of the 17 consortium members presented their key expertise, contribution to the project and main staff involved. The multidisciplinarity of the consortium consisting of SMEs, academic and scientific RTD partners, clinics and technology transfer organisations, underlines the complexity of the innovative concept of PANBioRA.

On the second meeting day,next steps and partner contributions for each task were discussed and defined. One of the main challenges of the project will be the integration of the different technologies into one system,making the determination of user requirementsfor the integrated PANBioRA systems an essential task, which was finalized during the meeting.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 760921andis conducted under the topic titled "Development of a reliable methodology for better risk management of engineered biomaterials in Advanced Therapy Medicinal Products and/or Medical Devices".

The PANBioRA consortium is composed of 17 partners from 11 European countries:

Participant organisation name

Country

·       Steinbeis 2i GmbH (Coordinator)

Germany

·       Dolmen Design and Innovation Limited

Ireland

·       Biodevice Systems s.r.o.

Czechia

·       Protobios OU

Estonia

·       Elvesys SAS

France

·       Steinbeis Advanced Risk Technologies Institute doo Kragujevac

Serbia

·       Steinbeis R-Tech

Germany

·       Commissariat A L’Energie Atomique Et Aux Energies Alternatives

France

·       Pro-active

Belgium

·       Aalto-Korkeakoulusaatio

Finland

·       TurgutOzal Education SHA

Albania

·       The University of Nottingham

UK

·       Agencia Estatal Consejo Superior de InvestigacionesCientíficas

Spain

·       Dublin City University

Ireland

·       Institut National de la Santé et de la Recherche Medicale

France

·       Centre Hospitalier Universitaire de Liège

Belgium

·       Protip Medical (Scientific Coordinator)

France

 

Project coordinator:

Scientific coordinator:               

Protip Medical SAS, Strasbourg

Dr. NihalEnginVrana | e.vrana@protipmedical.com | +33 388103063

 

Administrative coordinator:  

Steinbeis 2i GmbH

Dr. Mercedes Dragovits | dragovits@steinbeis-europa.de |+49 721 93519114

Contact

Media and Public Relations Office

pr@epoka.edu.al

+355 4 22 32 086

Share